Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 2/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.46 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18616624 | 1.00 | CHRNB4 (0.49) | CHRNB4CHRNA3CHRNB2CHRNA4ALOX5AP | |
| SCHEMBL5151878 | 0.90 | ALOX5AP (0.48) | CHRNB4CHRNA3CHRNB2CHRNA4ALOX5AP | |
| SCHEMBL5151883 | 0.90 | ALOX5AP (0.48) | CHRNB4CHRNA3CHRNB2CHRNA4ALOX5AP | |
| SCHEMBL18295390 | 0.87 | CHRNB4 (0.45) | CHRNB4CHRNA3CHRNB2CHRNA4ALOX5AP | |
| SCHEMBL18295362 | 0.87 | CHRNB4 (0.45) | CHRNB4CHRNA3CHRNB2CHRNA4ALOX5AP | |
| SCHEMBL8240624 | 0.86 | ALOX5AP (0.51) | CHRNB4CHRNA3CHRNB2CHRNA4ALOX5AP | |
| SCHEMBL9900728 | 0.86 | ALOX5AP (0.51) | CHRNB4CHRNA3CHRNB2CHRNA4ALOX5AP | |
| SCHEMBL9241908 | 0.86 | ALOX5AP (0.51) | CHRNB4CHRNA3CHRNB2CHRNA4ALOX5AP | |
| SCHEMBL8247133 | 0.86 | ALOX5AP (0.51) | CHRNB4CHRNA3CHRNB2CHRNA4ALOX5AP | |
| SCHEMBL13801184 | 0.86 | ALOX5AP (0.52) | CHRNB4CHRNA3CHRNB2CHRNA4ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407422-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-10 | — | — | US | disclosed |
| US-20190023701-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2019-01-24 | — | — | US | disclosed |
| WO-2017040449-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190023701-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | CHRNB4 1728/4885CHRNA3 1681/4885CHRNB2 2132/4885 |
| US-10407422-B2 | Triazolopyridine inhibitors of myeloperoxidase | EPX, MPO, SERPINB1 | CHRNB4 1728/4885CHRNA3 1681/4885CHRNB2 2132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.